glp 1 in spain GLP-1 Medications Are Revolutionizing Healthcare - UPS Healthcare™ Barcelona-spain October 13 2025 Glp-1
Description
An analysis of the clinical trial pipeline shows 39 GLP-1RA drugs in development across 34 companies, with only seven coming from the top 20 pharmaceutical firms
The drop-out rate due to adverse events stood at 10.3% for the high-dose group, compared to 7.7% for the 12 mg group, 5.1% for the 6 mg group, and 2.6% for the placebo group
That followed more than 40 similar letters in late 2025 and over 50 in September 2025
Beyond glucose control, GLP-1 receptor agonists improve insulin sensitivity, reduce systemic inflammation, and support cardiovascular health
